BiologybioRxiv
Ranked by formulaVerdict: NotableLigRNA: High-accuracy prediction of RNA-ligand binding sites via dynamic chemical complementarity and language model encoding
RNA-binding small molecules represent a validated therapeutic modality, yet pinpointing their exact RNA binding sites remains critical for mechanistic understanding and drug optimization.
Key numbers
- 7.4% and 18.4%
Caveats
- Preprint; not yet peer reviewed.
VerdictWorth a reader's time today.
Abstract
RNA-binding small molecules represent a validated therapeutic modality, yet pinpointing their exact RNA binding sites remains critical for mechanistic understanding and drug optimization. Experimental methods, while precise, are costly and low-throughput, necessitating robust computational alternatives. Approaches based on static feature concatenation may overlook input-dependent relationships between RNA residues and ligand functional groups. Here we present LigRNA, a graph neural network framework that predicts RNA-ligand binding sites through joint cross-modal encoding of both molecules. LigRNA integrates structure-guided language model embeddings with physicochemical features-solvent-accessible surface area and secondary structure types, to construct comprehensive RNA representations. Ligands are encoded as attributed molecular graphs via graph attention networks, preserving atom-level chemical topology rather than compressing molecules into fixed fingerprints. A cross-attention mechanism then enables dynamic, ligand-dependent modulation of RNA nucleotide attention, capturing context-specific interaction patterns. Benchmarked on TE9 and TE18 datasets, LigRNA achieves F1 scores of 0.73 and 0.58, improving on GATRsite by 7.4% and 18.4%, respectively. Ablation studies identify the RNA residual encoder as the most consistent contributor across the two benchmarks. The source code is freely available at https://github.com/WillowWang0216/LigRNA.
The editor's rubric
- Leverage4 / 5
- A general-purpose tool used across several fields (Adam, ResNet, LoRA, next-generation sequencing).
- Magnitude3 / 5
- Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
- Evidence3 / 5
- Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.
- Novelty3 / 5
- A genuinely new approach to an open problem.
- Trajectory2 / 5
- Some room to improve with obvious engineering.
- Stakes2 / 5
- Benefits a professional community (practitioners, clinicians, engineers).
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we propose); breadth (many tasks); gains (relative gain); novelty (alternative to status quo); verification (multiple benchmarks, ablations, experimental validation); stakes (prevention or cure).
How the score was computed
Desks place stronger verdicts first, then use this score to order work within the same verdict.
- Merit
- 6.1 / 10
- Adjusted merit
- 5.0 / 10
- Attention
- 0%
- Freshness
- 88%